<DOC>
	<DOC>NCT00421317</DOC>
	<brief_summary>The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.</brief_summary>
	<brief_title>Imatinib in Adult Patients With Metastatic Ocular Melanoma</brief_title>
	<detailed_description>Further study details as provided by Centre Oscar Lambret</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Metastatic ocular melanoma Age &gt; or = 18 years old Measurable metastases &gt; or = 10 mm according to RECIST criteria PSWHO &lt; or = 1 or IK &gt; 70 percent Normal hepatic function PNN &gt; 1500/mm3, platelets &gt; or = 100 000/mm3 Contraception Informed consent signed Patient with two prior lines of systemic treatment (chemotherapy, immunotherapy or association) Other evolutive neoplasic disease Severe hepatic insufficiency Severe renal insufficiency Somatic or psychiatric comorbidity incompatible with the protocol Leptomeningeal or cerebral metastatic dissemination Pregnant or lactating woman Other antitumoral treatment Patient participating to another clinical trial with an experimental drug Known hypersensitivity to Imatinib or one of its excipients Resecable single metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Ocular, Metastatic melanoma</keyword>
</DOC>